key: cord-0966621-5g7lxrqg
authors: Taquechel, Kiara; Diwadkar, Avantika R.; Sayed, Samir; Dudley, Jesse W.; Grundmeier, Robert W.; Kenyon, Chén C.; Henrickson, Sarah E.; Himes, Blanca E.; Hill, David A.
title: Pediatric Asthma Healthcare Utilization, Viral Testing, and Air Pollution Changes during the COVID-19 Pandemic
date: 2020-08-20
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2020.07.057
sha: e6ad306aa0b50b91b97c980cc4d3153f5828ebba
doc_id: 966621
cord_uid: 5g7lxrqg

ABSTRACT Background The COVID-19 pandemic caused dramatic changes in daily routines and healthcare utilization and delivery patterns in the United States. Understanding the influence of these changes and associated public health interventions on asthma care is important to determine effects on patient outcomes and identify measures that will ensure optimal future healthcare delivery. Objective We sought to identify changes in pediatric asthma-related healthcare utilization, respiratory viral testing, and air pollution during the COVID-19 pandemic. Methods For the time period Jan 17-May 17, 2015-2020, asthma-related encounters and weekly summaries of respiratory viral testing data were extracted from Children’s Hospital of Philadelphia (CHOP) electronic health records, and pollution data for four criteria air pollutants were extracted from AirNow. Changes in encounter characteristics, viral testing patterns, and air pollution before and after Mar 17, 2020, the date public health interventions to limit viral transmission were enacted in Philadelphia, were assessed and compared to data from 2015-2019 as a historical reference. Results After Mar 17, 2020, in-person asthma encounters decreased by 87% (outpatient) and 84% (emergency + inpatient). Video telemedicine, which was not previously available, became the most highly utilized asthma encounter modality (61% of all visits), and telephone encounters increased by 19%. Concurrently, asthma-related systemic steroid prescriptions and frequency of rhinovirus test positivity decreased, while air pollution levels did not substantially change, compared to historical trends. Conclusion The COVID-19 pandemic in Philadelphia was accompanied by changes in pediatric asthma healthcare delivery patterns, including reduced admissions and systemic steroid prescriptions. Reduced rhinovirus infections may have contributed to these patterns.

COVID-19, an illness caused by the SARS-CoV-2 virus, arose in late 2019 and rapidly 2 spread around the world. By June 2020, over 9 million cases and 469,000 deaths had 3 been reported worldwide, with 2.3 million cases and 122,000 deaths in the United 4

States (1). In response to , healthcare systems reoriented their delivery 5 structures to prepare for a dramatic increase in COVID-19 cases while attempting to 6 shield unaffected individuals from infection. Simultaneously, various local and national 7 public health interventions designed to limit viral transmission were enacted. At 8

Children's Hospital of Philadelphia (CHOP), the first COVID-19 patient tested positive 9

for SARS-CoV-2 on Mar 17, 2020. On this date, all non-essential businesses in 10 Philadelphia were prohibited from operating in person (3). Subsequently, the city 11 enacted a stay-at-home order and a closure of schools with the intent to limit physical 12 interactions among people and prevent transmission of the virus. Concern arose among 13 patients and their parents that visiting a hospital or doctor's office put them at increased 14 risk for contracting COVID-19, resulting in deferral of many in-person well-child and 15 routine follow-up care visits (4, 5) . For all of these reasons, many healthcare systems, 16

including CHOP, adopted video telemedicine (VTM) (6). 17

Asthma is one of the most common chronic childhood diseases, affecting one out 18 of twelve school-aged children in the United States (7), with a higher prevalence in 19

Philadelphia than the national mean (8, 9) . Pollution and respiratory virus exposure, in 20 particular Rhinovirus (10, 11) , can worsen asthma symptoms and trigger exacerbations 21 (12). For example, exposure to United States Environmental Protection Agency (EPA) 22 criteria air pollutants including particulate matter less than 2.5 microns (PM 2.5 ), 23 particulate matter less than 10 microns (PM 10 ), ozone, and nitrogen dioxide (NO 2 ), has 24 been associated with increased asthma exacerbations (13-16) and increased risk of 25 developing asthma (17). Viral respiratory infections are also associated with the majority 26 of pediatric asthma exacerbations (18), and people with asthma experience more 27 severe, longer-lasting respiratory viral infections than people without asthma (19) . 28

Based on these findings, it was thought that people with asthma were at risk for worse 29 COVID-19 outcomes (20, 21) , although subsequent observational studies have found 30 mixed results in support of this hypothesis (22) (23) (24) . 31 J o u r n a l P r e -p r o o f Page 7

The public health interventions adopted to slow the transmission of SARS-CoV-2 1 have altered environmental exposure profiles that also influence the risk of asthma 2 exacerbations. Infection prevention measures, including wearing face masks, washing 3 hands frequently, and social distancing as a result of stay-at-home orders and school 4 closures, reduce person-to-person transmission of all respiratory viruses. The decrease 5 in transportation and industrial activity resulting from COVID-19 restrictions has reduced 6 the emission of primary air pollutants worldwide (25, 26) , and there is current interest in 7 determining the extent to which these changes have affected asthma symptoms (27). In 8 this study, we sought to describe the impact of COVID-19 public health measures on 9 pediatric asthma-related healthcare utilization, respiratory virus testing in our 10 Emergency Department (ED), and pollution levels in the greater Philadelphia area. 11

Study Population. We extracted asthma patient encounter data corresponding to the 2 time period Jan 17-May 17 for the years 2015-2020 from the CHOP Care Network, 3 which consists of 48 outpatient primary and specialty care clinical sites, 4 urgent care 4 sites, 15 community hospital alliances, and a 557-bed quaternary care center in the 5 greater Philadelphia area. Data from this network has previously been validated as a 6 tool to assess regional disease trends (8,28). Asthma diagnosis was established based 7 on encounters having an International Classification of Diseases (ICD), 10 th Revision 8 code J45.nn. Accuracy of this definition was confirmed via manual review of 100 patient 9 charts. 10 11 Variable Selection. For each encounter, its type (i.e., inpatient, ED, outpatient, 12 telephone, and VTM) and date were extracted, along with the patient's gender, race, 13 ethnicity, date of birth, and payer type. Race was based on self-or parent/guardian-14 selection of one of the following categories: "White", "Black", "Asian or Pacific Islander", 15 or "Other". Subjects without a race selection were coded as "Unknown." Codified 16 asthma-related drug prescription data for all outpatient asthma-related prescriptions, 17 and for outpatient and inpatient systemic steroid prescriptions, were obtained from 18 CHOP provider prescription records (Table E1) Air Pollution Data. Hourly PM 2.5, PM 10 , ozone, and NO 2 measures obtained at EPA 1 monitoring sites in Philadelphia for the time period Jan 17-May 17 during years 2015-2 2020 were extracted from AirNow, an air quality data management system that reports 3 real-time and forecast air quality estimates (29). Because historical data was not 4 available for all pollutants in AirNow, we also downloaded daily summary files for the 5 time period Jan 17-May 17 during years 2015-2019 from Air Data, an EPA resource that 6 provides quality-assured summary air pollution measures collected from outdoor 7 regulatory monitors across the United States (30). In Philadelphia, the same monitoring 8 sites transmitted data to AirNow and AirData. 9 10 Data Analysis. Characteristics of encounters, viral test results, and pollutant levels from 11 the 60-day period before and after Mar 17, 2020 were compared to those from 2015-12 2019. A paired Student's T test was used to examine differences in systemic steroid 13 prescription rates between patients before and after Mar 17. For both viral testing and 14 pollution data, controlled interrupted time series (ITS) regression models were created 15 to identify statistically significant changes between the pre-and post-Mar 17 60-day 16 time frames that differed in 2020 compared to the 2015-2019 historical time period. 17

Significant differences between 2020 and historical data were determined based on p-18 values for regression coefficients corresponding to interaction terms of variables 19

representing pre-and post-Mar 17 status, the year(s) in question and/or days. For viral 20 testing, two way ANOVA and mixed-effect analysis were additionally utilized to test for 21 significant differences. To visualize pollution levels across Philadelphia during time 22

periods of interest, we generated 100m x 100m grid raster layers using inverse-23 Mar 17, 2020 in Philadelphia to limit COVID-19 spread, asthma healthcare visit 4 numbers and encounter types at CHOP were similar to 2015-2019 historical averages. 5

Overall, there was a 60% decrease in total daily asthma healthcare visits at CHOP 6 when comparing the 60 days before and after Mar 17, 2020 (102.44, standard deviation 7 (SD) 48.9, range 19-190 and 41.5, SD 25.7, range 0-94, respectively) (Figure 1) . 8

Before Mar 17, 2020, the average numbers of outpatient and hospital (emergency 9 department + inpatient) daily asthma encounters were 72.5 (SD 46.2, range 0-154) and 10 25.7 (SD 6.6, range 0-41), respectively. After Mar 17, 2020, the average number of daily 11 outpatient encounters decreased by 87% to 9.2 (SD 8.2, range 0-44), while hospital 12 encounters decreased by 84% to 4.2 (SD 3.8, range 0-18). Concurrently, asthma 13 telephone encounters across the network increased by 19% from a daily average of 4.3 14 (SD 4.2, range 0-24) to 5.1 (SD 5.3, range 0-21) after Mar 17, 2020. VTM was not 15 available prior to Mar 17, 2020 but was quickly adopted: asthma VTM encounters 16 averaged 23.0 per day (SD 19.9 range 0-70) and accounted for 61% of all encounters 17 

Interventions. Comparison of pre-and post-Mar 17, 2020 CHOP prescription patterns 2 found that the relative proportions of most outpatient asthma-related prescriptions were 3 similar before and after introduction of COVID-19 public health interventions ( Figure  4 2A). One exception was outpatient systemic steroid prescriptions, which were 5

proportionally reduced compared to other asthma-related medications after the 6 introduction of COVID-19 public health interventions (Figure 2A) . When limiting the 7 comparison to patients who had at least one systemic steroid prescription from any 8 primary asthma encounter (outpatient, emergency, or inpatient) between Jan 17 and 9

May 17, 2020, there was a 83% decrease in systemic steroid prescriptions ( Figure 2B) . 10

Black patients, and patients with Medicaid coverage represented the highest proportion 11 of steroid prescription encounters between Mar 17 and May 17, 2020 (70% and 63%, 12 respectively) ( Table E2) . Mar 17, 2020 ( Figure 3D ). Controlled ITS results found some significant changes when 27 comparing 2020 data to prior years for all three of the four viruses (not for Influenza A), 28

though year-to-year variability was observed, consistent with variable timing of viral 29 seasons ( Figure E1 ). For example, significant differences were identified for RSV in the 30 period prior to Mar 17, though some prior years had higher rates of positive testing than 31 J o u r n a l P r e -p r o o f Page 13 in 2020, while others had lower ( Figure E1C and Table 2 Mar 17, 2020 pollution levels (Table 3; Figure 4A ) found that the daily average of 8 PM 2.5 , PM 10 , and NO 2 levels decreased by 29.0% (2.17 µg/m 3 ), 18.2% (3.13 µg/m 3 ), 9

and 44.1% (6.75 ppb), respectively, while ozone levels increased by 43.4% (10.08 ppb). 10

Historical data for 2015-2019 showed comparable changes pre-and post-Mar 17: 11

AirNow estimates for PM 2.5 levels decreased by 34.2% (3.88 µg/m 3 ) and ozone 12 increased by 52.4% (10.9 ppb); AirData estimates found that PM 2.5 levels decreased by 13 29.2% (3.15 µg/m 3 ), PM 10 by 11.6% (2.63 µg/m 3 ), and NO 2 by 28.5% (5.49 ppb), while 14 ozone increased by 46.4% (10.69 ppb). While some of these changes differed 15 significantly across the full range of days (Jan 17-May 17), year, and/or before and after 16 the Mar 17 date, none of the changes were statistically significant compared to historical 17 trends observed across the pre-and post-Mar 17 60-day time period (Table E3) . 18

Specifically, PM 2.5 and PM 10 had significantly decreased levels in 2020 compared to 19 prior years during the days Jan 17-May 17; PM 2.5 significantly decreased after Mar 17 in 20 all years whether using AirNow or AirData historical data (p<0.05); ozone had 21 significantly higher levels after Mar 17 and across all days whether using AirNow or 22

AirData historical data (p<0.001); and NO 2 significantly decreased across days (p<0.05) 23 with no change before or after Mar 17 or by year. Figure 4B shows the raster of PM 2.5 24 levels in Philadelphia for the 60-day pre-and post-Mar 17 periods along with the 25 location of air monitoring stations that recorded PM 2.5 measures. 26

We found that public health interventions designed to limit SARS-CoV-2 2 transmission in the Philadelphia region were associated with increased VTM and 3 decreased overall asthma encounters, systemic steroid prescriptions, and rhinovirus 4 positivity in our ED (Figure 5) . We previously noted an overall decrease in ED utilization 5 at CHOP (32), a pattern consistent with that observed in other regions of the country 6 that included a shift away from in-person care and towards VTM-based care (33). Our 7 observed decrease in the overall asthma disease burden is also consistent with national 8 survey data (33). 9

After Mar 17, 2020, VTM became the most utilized asthma encounter modality at 10 CHOP, enabling asthma patients to access care while adhering to stay-at-home 11

guidelines. Prior studies have demonstrated the utility of VTM to facilitate care delivery 12

to underserved rural populations and as a viable substitute for both routine and acute in-13 person asthma care visits (34,35). However, the rapid introduction of VTM across the 14 country represents a new, and as such, understudied care model. Black children 15

accounted for the majority of outpatient and hospital care after Mar 17, 2020, yet they 16 only represented 26% of VTM encounters. We were unable to determine whether this 17 observed difference by race in VTM care was due to patient preference, differences in 18 access to VTM or some other factor. Future studies should consider this issue carefully 19 in light of well-known disparities in asthma prevalence, severity, and exacerbations by 20 race, ethnicity, and socioeconomic status in the United States (36-38), as well as 21 concern for a potential "digital divide" in telemedicine (39-41). 22

in asthma encounters we observed. Most notably, we found that cases of positive RV 24 testing decreased following the introduction of public health interventions designed to 25 limit viral transmission of SARS-CoV-2. This is relevant as RV is a key cause of asthma 26 exacerbations (10,11). The other three viruses examined (IFV-A, IFV-B, RSV) were 27 waning by Mar 17, 2020, and as such likely did not play as active of a role in asthma 28 exacerbations that occurred after this date. However, we note that we were limited 29 when comparing viral data trends across years because of variability in seasonal onset 30 and peak timing. This variability led to mixed results on the impact of COVID-19 public 1 health interventions on RSV. Overall, a clinically impactful effect of COVID-19 related 2 public health interventions on RSV was unlikely, while the decrease in RV may have 3 contributed to a decrease in asthma exacerbations after Mar 17. 4

Air pollution levels are known to vary according to season: PM 2.5 and PM 10 5 concentrations across the United States are relatively higher in summer and lower in 6 winter (42), while ground-level ozone and NO 2 are inversely related, with levels peaking 7 in summer and winter, respectively (43). Our results for each of these four criteria air 8 pollutants across the Jan 17-May 17 time frame in Philadelphia is consistent with known 9 seasonal trends. While we did not observe statistically significant changes following 10 COVID-19 public health interventions for these four pollutants, the dramatic reduction in 11 vehicular traffic and some industrial activity likely reduced levels of specific pollutants 12 not captured by EPA regulatory monitors. NO 2 and PM 10 comparisons were limited 13 because they involved two different sources of data: AirNow and AirData. While the 14 same monitoring sites provided data to these publicly available resources, they differed 15 in that AirData releases quality-assured data, while AirNow releases real-time 2015-2019 revealed that they were broadly similar. Additionally, controlled ITS results 20 were similar whether AirNow or AirData historical measures were used for these two 21 pollutants (Table E2) controller medication prescriptions as the COVID-19 pandemic began, given initial 1 concern that those with asthma had increased susceptibility to more severe outcomes 2 with SARS-CoV-2 infection. In addition, fear of contracting COVID-19 may have 3 reduced the likelihood of an individual accessing in-person care, as well as increased 4 adherence to controller medications (44). Finally, just as social distancing and increased 5 time spent indoors may have limited patient exposure to viruses and outdoor pollution, 6 these measures may have also decreased exposure to outdoor environmental allergens 7 that are known triggers of pediatric asthma (45). School closures may have additionally 8 resulted in reduced exposure to allergens, as school environments can be sources of 9 allergens that increase asthma morbidity (46,47). 10

Our study is subject to additional limitations worth noting. The demographic, 11 healthcare utilization, and viral testing data was derived from a single institution and 12 collected as part of routine care. Therefore, our results may not generalize to other 13 regions and are observational in nature. We relied on primary ICD codes to identify 14 asthma encounters, which may be affected by billing or administrative constraints, and 15 hence may have introduced bias in our data collection. Our prescription data is 16 incomplete in that patients may have sought care outside of our network, and it is 17 limited in that we do not have information on prescriptions filled or adherence. Further, 18

we observed an increase in steroid prescriptions in 2020 as compared with prior years. 19

This increase could be due to shifts in our patient acuity, or provider prescription 20 practices. Finally, use of EHR-derived data is subject to bias and error more broadly, 21 which we were unable to control for, although most errors in the data would have biased 22 us toward not observing significant changes. As such, future studies are warranted to 23 refine our findings and improve our understanding of the effects of the COVID-19 24 pandemic on asthma care, triggers, and clinical outcomes. 25 Acknowledgements and Funding: We thank Rebecca A. Hubbard, PhD for statistical 1 advice. This work was supported by the National Institutes of Health DK116668 (DAH), 2 R01HL133433 (BEH), R01HL141992 (BEH), P30ES013508, K08AI135091 (SEH), 3 R25HL084665 (KT), the American College of Allergy Asthma and Immunology (DAH), 4

American College of Allergy Asthma and Immunology (DAH), the American Partnership 5

For Eosinophilic Disorders (DAH), the Burroughs Wellcome Fund (SEH), and CHOP 6

Research Institute Developmental Awards (DAH and SEH). Figure 5 was created with 7

BioRender. 8 9

The content of this work is the responsibility of the authors and does not necessarily 10 represent the official views of the National Institutes of Health. Impact of coronavirus outbreak on NO 2 pollution assessed using TROPOMI and 5 OMI observations. Geophys Racial disparities in asthma-related health care use in the National Heart, Lung, 5

and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol. color. The dashed line after week 9 (Mar 17) is the predicted data based on the prior 2 results, and the uninterrupted line is the actual data from 2020 (exact data also plotted 3 as circles). Significance testing via ANOVA (F) and details in Table 2 for (G). 

Positive Influenza A of all Influenza A tests Influenza A

% Positive Rhinovirus of all Rhinovirus tests Rhinovirus

Tables 1 Table 1 . Demographic characteristics of asthma subjects by time period and encounter type. 

Non-Hispanic/Latino 20,997 (91%)

Before 2000 J o u r n a l P r e -p r o o f